Gamunex-C: payments to doctors
Payments that named Gamunex-C as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.1M
- Providers
- 5,922
- Transactions
- 20,995
- Average per transaction
- $100
The per-transaction average — $100 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,922 providers the average total is $354, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Grifols USA, LLC | $1,900,122 | 90.7% |
| Grifols Shared Services North America, Inc. | $180,843 | 8.6% |
| Grifols, S.A. | $13,100 | 0.6% |
| Grifols Therapeutics LLC | $1,400 | 0.1% |